KUBOTA Kazuo, FKUDA Hiroshi, ITO Masatoshi, INOUE Tomio, ENDO Keigo, TADOKORO Masanori, ISIGAKI Takeo, NAKAMOTO Hiroshi, KONISHI Junji, KUWABARA Yasuo, SASAKI Masayuki, KAWABE Joji, OCHI Hironobu, YONEKURA Yoshiharu, ISHIDA Yoshio, FUKUCHI Kazuki, IIDA Akihiko, HIGASHI Kotaro, YAMAMOTO Itaru, IDE Mitsuru, YASUDA Seiei, TATSUMI Mitsuaki, NISHIMURA Tsunehiko, KOSAKA Noboru, HARA Toshihiko, ITO Kengo, TORIZUKA Tatsuro, OUCHI Yasuomi, TORIZUKA Kanji
RADIOISOTOPES, 49(3) 121-130, Mar 15, 2000 Peer-reviewed
Diagnostic accuracy of positron emission tomography (PET) using18F-fluorodeoxyglucose for lung cancer has been evaluated as a retrospective multi-center survey in Japan. A total of 600 studies were collected from the 15 institutions. For the differential diagnosis between benign and malignant tumors, sensitivity, specificity, and accuracy were 81.1 % (322/397), 63.5% (54/85), 78.9% (376/482), respectively. For the staging diagnosis of lung cancer patients, whole-body PET was superior to CT/MRI in 21.3% (35/164), equal to CT/MRI in 73.8% (121/164), inferior to CT/MRI in 4.9% (8/164) . It was assumed that sensitivity, specificity, and accuracy of whole-body FDDG-PET for the diagnosis of metastatic foci were 88.3%, each. Cost-effectiveness analysis of FDG-PET for the diagnosis of lung cancer in Japan was performed on the basis of these data. The strategy of whole-body FDG-PET for the staging diagnosis of lung cancer showed a saving of 43, 000 yen per patient as a result of improving staging of lung cancer and avoiding unnecessary surgery. The total saving in diagnosis and surgery of lung cancer in Japan will be 1.5 billion yen per year (1.9% of total cost in diagnosis and surgery) .